Nutritional consequences and nutrition therapy in Crohn's disease

被引：32
作者：
Hebuterne, X. [1 ,2 ,3 ,4 ]
Filippi, J. [1 ,2 ,3 ]
Al-Jaouni, R. [1 ,2 ,3 ]
Schneider, S. [1 ,2 ,3 ]
机构：
[1] CHU Nice, Serv Gastroenterol, F-06202 Nice 03, France
[2] CHU Nice, Hop Archet 2, Nutr Clin, F-06202 Nice, France
[3] Univ Nice Sophia Antipolis, Fac Med, F-06107 Nice, France
[4] INSERM, ERI Nice 21, F-06107 Nice, France
来源：
GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE | 2009年 / 33卷
关键词：
INFLAMMATORY-BOWEL-DISEASE; TOTAL PARENTERAL-NUTRITION; RANDOMIZED CONTROLLED-TRIAL; BONE-MINERAL DENSITY; ENTERAL NUTRITION; ENERGY-EXPENDITURE; SUBSTRATE OXIDATION; CLINICAL REMISSION; ULCERATIVE-COLITIS; POLYMERIC DIET;
D O I：
10.1016/S0399-8320(09)73159-8
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
75% of hospital patients with Crohn's disease (CD) suffer from malnutrition and one third of CD patients have a body mass index below 20. Inflammatory bowel diseases (IBD) patients have many vitamin and nutrient deficiencies which can lead to important consequences such as hyperhomocysteinemia which is associated with a higher risk of thromboembolic disease. Nutritional deficiencies in IBD patients are the result of insufficient intake, malabsorption and protein-losing enteropathy as well as the metabolic distubances directly induced by the chronic disease and its treatments, in particular corticosteroids. Screening for nutritional deficiencies in chronic disease patients is warranted. Managing the deficiencies involves simple nutritional guidelines, vitamin supplements, and nutritional support in the worst cases, in particular in children in order to limit the impact of IBD on growth. In active CD, enteral nutrition is the first line therapy in children and should be used as sole therapy in adults mainly when treatment with corticosteroids is not feasible. (C) 2009 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：S235 / S244
页数：10
相关论文
共 54 条
[1]   METABOLIC BONE ASSESSMENT IN PATIENTS WITH INFLAMMATORY BOWEL-DISEASE [J].
ABITBOL, V ;
ROUX, C ;
CHAUSSADE, S ;
GUILLEMANT, S ;
KOLTA, S ;
DOUGADOS, M ;
COUTURIER, D ;
AMOR, B .
GASTROENTEROLOGY, 1995, 108 (02) :417-422
[2]   Double-blind randomized controlled trial of glutamine-enriched polymeric diet in the treatment of active Crohn's disease [J].
Akobeng, AK ;
Miller, V ;
Stanton, J ;
Elbadri, AM ;
Thomas, AG .
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2000, 30 (01) :78-84
[3]   Energy metabolism and substrate oxidation in patients with Crohn's disease [J].
Al-Jaouni, R ;
Hébuterne, X ;
Pouget, I ;
Rampal, P .
NUTRITION, 2000, 16 (03) :173-178
[4]  
Al-Jaouni R, 2002, AM J GASTROENTEROL, V97, P2843
[5]  
ALJAOUNI R, 2003, GASTROENTEROL CLIN B, V27, pA147
[6]   Prophylactic effect of dietary glutamine supplementation on interleukin 8 and tumour necrosis factor alpha production in trinitrobenzene sulphonic acid induced colitis [J].
Ameho, CK ;
Adjei, AA ;
Harrison, EK ;
Takeshita, K ;
Morioka, T ;
Arakaki, Y ;
Ito, E ;
Suzuki, I ;
Kulkarni, AD ;
Kawajiri, A ;
Yamamoto, S .
GUT, 1997, 41 (04) :487-493
[7]   Altered subjective appetite parameters in Crohn's disease patients [J].
Bannerman, E ;
Davidson, I ;
Conway, C ;
Culley, D ;
Aldhous, MC ;
Ghosh, S .
CLINICAL NUTRITION, 2001, 20 (05) :399-405
[8]  
BEATTIE RM, 1994, ALIMENT PHARM THERAP, V8, P609
[9]  
Bernstein CN, 2003, AM J GASTROENTEROL, V98, P2468, DOI [10.1016/S0002-9270(03)00661-0, 10.1111/j.1572-0241.2003.07676.x]
[10]  
Capristo E, 1999, AM J CLIN NUTR, V69, P339
123456